/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
voxeljet AG Reports Financial Results for the First Quarter Ended March 31, 2019
FRIEDBERG, Germany–(BUSINESS WIRE)–voxeljet AG (NYSE: VJET) (the “Company”, or “voxeljet”), a leading
provider of high-speed, large-format 3D printers and on-demand parts
services to industrial and commercial customers, today announced
consolidated financial results for the first quarter ended March 31,
2019.
Highlights – First Quarter 2019(1)
-
Total revenues for the first quarter increased 10.2% to kEUR 5,565
from kEUR 5,052 -
Gross profit margin decreased to 34.4% from 42.2% to kEUR 1,913 from
kEUR 2,133 - Systems revenues increased 75.6% to kEUR 2,415 from kEUR 1,375
- Services revenues decreased 14.3% to kEUR 3,150 from kEUR 3,677
- Reaffirm full year 2019 guidance
(1)Certain comparative figures for the 3-month
period ended March 31, 2018 were restated for immaterial
errors. For further information, see Note 9 of the Q3-2018 condensed
consolidated interim financial statements.
Dr. Ingo Ederer, Chief Executive Officer of voxeljet, commented, “We had
a strong first quarter with results that confirm why we are so excited
about our potential to establish a new manufacturing standard. Just
recently, we installed the first print engine into VJET X: This print
engine is the heart of our new additive mass manufacturing solution and
I firmly believe one of the most advanced piece of technology in the
whole additive manufacturing industry. The shifts we have made to our
business and our deeper focus on the three core areas of innovation,
integration and speed are igniting the next phase of growth and
profitability for voxeljet.”
First Quarter 2019 Results
Revenues for the first quarter of 2019 increased by 10.2% to kEUR 5,565
compared to kEUR 5,052 in the first quarter of 2018.
Revenues from our Systems segment, which focuses on the development,
production and sale of 3D printers, increased 75.6% to kEUR 2,415 in the
first quarter of 2019 from kEUR 1,375 in last year’s first quarter. The
Company delivered two new and one used and refurbished 3D printer in the
first quarter of 2019, compared to two used and refurbished printers
delivered in last year’s first quarter. Systems revenues also include
all Systems-related revenues from consumables, spare parts and
maintenance. The increase of revenues from our Systems segment was
mainly due to higher revenues from Systems-related revenues, while
revenue from the sale of 3D printers slightly increased. The increase of
Systems-related revenues reflects the higher installed base of 3D
printers in the market and the associated growth in aftersales
activities. Systems revenues represented 43.4% of total revenues in the
first quarter of 2019 compared to 27.2% in last year’s first quarter.
Revenues from our Services segment, which focuses on the printing of
on-demand parts for our customers, decreased 14.3% to kEUR 3,150 in the
first quarter of 2019 from kEUR 3,677 in the comparative period of 2018.
This was mainly due to lower revenue contributions from our German
operation. We received a lower number of orders mainly reflecting a
lower demand from the automotive industry. This was partially offset by
increased revenue contributions from our subsidiary voxeljet America
Inc. (“voxeljet America”). The increase in revenue at our American
service center was mainly attributable to a volume contract which we
entered into during the second quarter of 2018.
Cost of sales was kEUR 3,652 for the first quarter of 2019 compared to
kEUR 2,919 for the first quarter of 2018.
Gross profit and gross profit margin were kEUR 1,913 and 34.4%,
respectively, in the first quarter of 2019 compared to kEUR 2,133 and
42.2%, respectively in the first quarter of 2018.
Gross profit for our Systems segment increased to kEUR 829 in the first
quarter of 2019 from kEUR 381 in the first quarter of 2018. Gross profit
margin for this segment increased to 34.3% in the first quarter of 2019
compared to 27.7% in the first quarter of 2018. This was mainly due to
higher gross profit margin contributions from Systems-related revenues
resulting from a more favorable ratio of revenues to fixed costs
compared to last year’s first quarter.
Gross profit for our Services segment significantly decreased to
kEUR 1,084 in the first quarter of 2019 compared to kEUR 1,752 in the
first quarter of 2018. The gross profit margin for this segment
decreased to 34.4% in the first quarter of 2019 from 47.6% in the first
quarter of 2018. This was mainly related to lower gross profit margin
from the German service center as a result of lower utilization. Our
subsidiary voxeljet America also contributed lower gross profit margin
due to higher depreciation expense, as we added additional 3D printers
to our American service center during the third quarter of 2018,
including one VX4000 system.
Selling expenses remained nearly unchanged at kEUR 1,676 for the first
quarter of 2019 compared to kEUR 1,736 in the first quarter of 2018,
despite an increase in revenues. We incurred higher shipping and
packaging expenses, which vary from quarter to quarter depending on
quantity and types of products, as well as the destinations where those
goods are being delivered.
Administrative expenses were kEUR 1,439 for the first quarter of 2019
compared to kEUR 1,232 in the first quarter of 2018. This was mainly due
to an increase in headcount resulting in higher personnel expenses as
part of management’s remediation efforts on the material weakness
identified in the prior year. In addition, we incurred higher consulting
fees as part of our project to expand our Enterprise Resource Planning
(“ERP”) system. We have hired additional employees in the IT-Team for
the management of SAP ERP system related tasks.
Research and development (“R&D”) expenses increased to kEUR 1,705 in the
first quarter of 2019 from kEUR 1,597 in the first quarter of 2018. The
increase of kEUR 108 was mainly due to higher personnel expenses as a
result of a slight increase in headcount.
Other operating expenses in the first quarter of 2019 were kEUR 13
compared to kEUR 358 in the prior year period. This was mainly due to
lower losses from foreign currency transaction for the first quarter of
2019 compared to the first quarter of 2018.
Other operating income was kEUR 978 for the first quarter of 2019
compared to kEUR 402 in the first quarter of 2018. The increase was
mainly due to higher gains from foreign currency transactions.
The changes in foreign currency gains and losses were primarily driven
by the valuation of the intercompany loans granted by the parent company
to our UK and US subsidiaries.
Operating loss was kEUR 1,942 in the first quarter of 2019, compared to
an operating loss of kEUR 2,388 in the comparative period in 2018. The
improvement was primarily related to a significant increase of other
operating income partially offset by a lower gross profit.
Financial result was negative kEUR 858 in the first quarter of 2019,
compared to a financial result of positive kEUR 678 in the comparative
period in 2018. The significant decrease was mainly driven by the
revaluation of the derivative financial instruments in connection with
the European Investment Bank loan.
Net loss for the first quarter of 2019 was kEUR 2,788 or EUR 0.57 per
share, as compared to net loss of kEUR 1,716, or EUR 0.46 per share, in
the first quarter of 2018.
Based on a conversion rate of five American Depositary Shares (“ADSs”)
per ordinary share, net loss was at EUR 0.11 per ADS for the first
quarter of 2019, compared to a net loss of EUR 0.09 per ADS for the
first quarter of 2018. Earnings per share is computed by dividing net
income attributable to stockholders of the parent by the
weighted-average number of ordinary shares outstanding during the
periods. Earnings per ADS is calculated by dividing the above earnings
per share by five as each ordinary share represents five ADSs.
Business Outlook
Our revenue guidance for the second quarter of 2019 is expected to be in
the range of kEUR 5,000 to kEUR 5,250.
We reaffirm our guidance for the full year ending December 31, 2019:
-
Full year revenue is expected to be in the range of kEUR 27,000 to
kEUR 30,000 - Gross margin is expected to be above 40%
-
Operating expenses for the full year are expected as follows: selling
and administrative expenses are expected to be in the range of
kEUR 12,000 to kEUR 12,500 and R&D expenses are projected to be
between approximately kEUR 5,500 and kEUR 6,000. Depreciation and
amortization expense is expected to be between kEUR 3,750 and
kEUR 4,000. -
Adjusted EBITDA for the second half of the year ending December 31,
2019 is expected to be neutral-to-positive. Adjusted EBITDA is defined
as net income (loss), as calculated under IFRS accounting principles
before interest (income) expense, provision (benefit) for income
taxes, depreciation and amortization, and excluding other operating
(income) expense resulting from foreign exchange gains or losses on
the intercompany loans granted to the subsidiaries. -
Capital expenditures are projected to be in the range of kEUR 2,000 to
kEUR 2,500, which primarily includes ongoing investments in our global
subsidiaries.
Our total backlog of 3D printer orders at March 31, 2019 was kEUR 3,422,
which represents six 3D printers. This compares to a backlog of kEUR
3,392 representing six 3D printers, at December 31, 2018. As production
and delivery of our printers is generally characterized by lead times
ranging between three to nine months, the conversion rate of order
backlog into revenue is dependent on the equipping process for the
respective 3D printer as well as the timing of customers’ requested
deliveries.
At March 31, 2019, we had cash and cash equivalents of kEUR 8,482 and
held kEUR 8,924 of investments in bond funds and kEUR 1,253 in one note
receivable, which are included in current financial assets on our
consolidated statements of financial position.
Webcast and Conference Call Details
The Company will host a conference call and webcast to review the
results for the first quarter on Friday, May 17, 2019 at 8:30 a.m.
Eastern Time. Participants from voxeljet will include its Chief
Executive Officer, Dr. Ingo Ederer, and its Chief Financial Officer,
Rudolf Franz, who will provide a general business update and respond to
investor questions.
Interested parties may access the live audio broadcast by dialing
1-877-705-6003 in the United States/Canada, or 1-201-493-6725 for
international, Conference Title “voxeljet AG First Quarter 2019
Financial Results Conference Call”. Investors are requested to access
the call at least five minutes before the scheduled start time in order
to complete a brief registration. An audio replay will be available
approximately two hours after the completion of the call at
1-844-512-2921 or 1-412-317-6671, Replay Conference ID number 13690018.
The recording will be available for replay through May 24, 2019.
A live webcast of the call will also be available on the investor
relations section of the Company’s website. Please go to the website https://event.webcasts.com/starthere.jsp?ei=1241565&tp_key=90fb6173de
at least fifteen minutes prior to the start of the call to register,
download and install any necessary audio software. A replay will also be
available as a webcast on the investor relations section of the
Company’s website.
Non-IFRS Measure
The Company uses Adjusted EBITDA as a supplemental financial measure of
its financial performance. Adjusted EBITDA is defined as net income
(loss), as calculated under IFRS accounting principles, interest
(income) expense, provision (benefit) for income taxes, depreciation and
amortization, and excluding other (income) expense resulting from
foreign exchange gains or losses on the intercompany loans granted to
the subsidiaries. Management believes Adjusted EBITDA to be an important
financial measure because it excludes the effects of fluctuating foreign
exchange gains or losses on the intercompany loans granted to its
subsidiaries. We are unable to reasonably estimate the potential
full-year financial impact of foreign currency translation because of
volatility in foreign exchange rates. Therefore, we are unable to
provide a reconciliation our forward-looking guidance for non-GAAP
Adjusted EBITDA without unreasonable effort as certain information
necessary to calculate such measure on an IFRS basis is unavailable,
dependent on future events outside of our control and cannot be
predicted without unreasonable efforts by the Company.
Management regularly uses both IFRS and non-IFRS results and
expectations internally to assess its overall performance of the
business, making operating decisions, and forecasting and planning for
future periods. Management believes that Adjusted EBITDA is a useful
financial measure to the Company’s investors as it helps investors
better understand and evaluate the projections our management board
provides. The Company’s calculation of Adjusted EBITDA may not be
comparable to similarly titled financial measures reported by other peer
companies. Adjusted EBITDA should not be considered as a substitute to
financial measures prepared in accordance with IFRS.
Exchange rate
This press release contains translations of certain U.S. dollar amounts
into euros at specified rates solely for the convenience of readers.
Unless otherwise noted, all translations from U.S. dollars to euros in
this press release were made at a rate of USD 1.1235 to EUR 1.00, the
noon buying rate of the Federal Reserve Bank of New York for the euro on
March 31, 2019.
About voxeljet
voxeljet is a leading provider of high-speed, large-format 3D
printers and on-demand parts services to industrial and commercial
customers. The Company’s 3D printers employ a powder binding, additive
manufacturing technology to produce parts using various material sets,
which consist of particulate materials and proprietary chemical binding
agents. The Company provides its 3D printers and on-demand parts
services to industrial and commercial customers serving the automotive,
aerospace, film and entertainment, art and architecture, engineering and
consumer product end markets. For more information, visit http://www.voxeljet.de/en/.
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements concerning our
business, operations and financial performance. Any statements that are
not of historical facts may be deemed to be forward-looking statements.
You can identify these forward-looking statements by words such as
‘‘believes,’’ ‘‘estimates,’’ ‘‘anticipates,’’ ‘‘expects,’’ ‘‘projects,’’
‘‘plans,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘could,’’ ‘‘might,’’ ‘‘will,’’
‘‘should,’’ ‘‘aims,’’ or other similar expressions that convey
uncertainty of future events or outcomes. Forward-looking statements
include statements regarding our intentions, beliefs, assumptions,
projections, outlook, analyses or current expectations concerning, among
other things, our results of operations, financial condition, business
outlook, the industry in which we operate and the trends that may affect
the industry or us. Although we believe that we have a reasonable basis
for each forward-looking statement contained in this press release, we
caution you that forward-looking statements are not guarantees of future
performance. All of our forward-looking statements are subject to known
and unknown risks, uncertainties and other factors that are in some
cases beyond our control and that may cause our actual results to differ
materially from our expectations, including those risks identified under
the caption “Risk Factors” in the Company’s Annual Report on Form 20-F
and in other reports the Company files with the U.S. Securities and
Exchange Commission, as well as the risk that our revenues may fall
short of the guidance we have provided in this press release. Except as
required by law, the Company undertakes no obligation to publicly update
any forward-looking statements for any reason after the date of this
press release whether as a result of new information, future events or
otherwise.
CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Notes | 3/31/2019 | 12/31/2018 (1) | ||||
(€ in thousands) | ||||||
unaudited | ||||||
Current assets | 36,519 | 37,936 | ||||
Cash and cash equivalents | 7 | 8,482 | 7,402 | |||
Financial assets | 7 | 10,177 | 12,905 | |||
Trade receivables, net | 4,857 | 6,030 | ||||
Inventories | 4 | 11,156 | 10,064 | |||
Income tax receivables | 37 | 13 | ||||
Other assets | 1,810 | 1,522 | ||||
Non-current assets | 35,371 | 31,416 | ||||
Financial assets | 7 | 1,632 | 2,234 | |||
Intangible assets | 1,404 | 1,420 | ||||
Property, plant and equipment, net | 2, 5 | 32,255 | 27,675 | |||
Investments in joint venture | 32 | 33 | ||||
Other assets | 48 | 54 | ||||
Total assets | 71,890 | 69,352 |
Notes | 3/31/2019 | 12/31/2018 (1) | ||||
Current liabilities | 6,732 | 6,302 | ||||
Trade payables | 7 | 2,507 | 2,945 | |||
Contract liabilities | 7 | 1,027 | 817 | |||
Financial liabilities | 2, 7 | 1,377 | 850 | |||
Other liabilities and provisions | 6 | 1,821 | 1,690 | |||
Non-current liabilities | 20,780 | 16,575 | ||||
Deferred tax liabilities | 63 | 76 | ||||
Financial liabilities | 2, 7 | 20,539 | 16,321 | |||
Other liabilities and provisions | 6 | 178 | 178 | |||
Equity | 44,378 | 46,475 | ||||
Subscribed capital | 4,836 | 4,836 | ||||
Capital reserves | 87,572 | 86,803 | ||||
Accumulated deficit | (49,184) | (46,400) | ||||
Accumulated other comprehensive income | 907 | 1,201 | ||||
Equity attributable to the owners of the company | 44,131 | 46,440 | ||||
Non-controlling interest | 247 | 35 | ||||
Total equity and liabilities | 71,890 | 69,352 |
See accompanying notes to unaudited condensed consolidated interim
financial statements.
(1)The Company has initially applied IFRS 16 as of January 1,
2019, using the modified retrospective approach. Under this approach,
comparative information is not restated and the cumulative effect of
initially applying IFRS 16 is recognized in retained earnings at the
date of initial application. For further information, see Note 2 of the
condensed consolidated interim financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)
Three months ended March 31, | ||||||
Notes | 2019 | 2018 (1) (2) | ||||
(€ in thousands except share and share data) | ||||||
Revenues | 9, 10 | 5,565 | 5,052 | |||
Cost of sales | (3,652) | (2,919) | ||||
Gross profit | 9 | 1,913 | 2,133 | |||
Selling expenses | (1,676) | (1,736) | ||||
Administrative expenses | (1,439) | (1,232) | ||||
Research and development expenses | (1,705) | (1,597) | ||||
Other operating expenses | (13) | (358) | ||||
Other operating income | 978 | 402 | ||||
Operating loss | (1,942) | (2,388) | ||||
Finance expense | 8 | (917) | (268) | |||
Finance income | 8 | 59 | 946 | |||
Financial result | 8 | (858) | 678 | |||
Loss before income taxes | (2,800) | (1,710) | ||||
Income taxes | 12 | (6) | ||||
Net loss | (2,788) | (1,716) | ||||
Debt investment at FVOCI – net change in fair value | 106 | (15) | ||||
Foreign currency translation differences | (400) | (64) | ||||
Other comprehensive income | (294) | (79) | ||||
Total comprehensive loss | (3,082) | (1,795) | ||||
Loss attributable to: | ||||||
Owners of the Company | (2,784) | (1,710) | ||||
Non-controlling interests | (4) | (6) | ||||
(2,788) | (1,716) | |||||
Total comprehensive loss attributable to: | ||||||
Owners of the Company | (3,078) | (1,789) | ||||
Non-controlling interests | (4) | (6) | ||||
(3,082) | (1,795) | |||||
Weighted average number of ordinary shares outstanding | 4,836,000 | 3,720,000 | ||||
Loss per share – basic/ diluted (EUR) | (0.58) | (0.46) |
See accompanying notes to unaudited condensed consolidated interim
financial statements.
(1)The Company has initially applied IFRS 16 as of January 1,
2019, using the modified retrospective approach. Under this approach,
comparative information is not restated and the cumulative effect of
initially applying IFRS 16 is recognized in retained earnings at the
date of initial application. For further information, see Note 2 of the
condensed consolidated interim financial statements.
(2)Certain comparative figures for the 3-month period ended
March 31, 2018 were restated for immaterial errors. For further
information, see Note 9 of the Q3-2018 condensed consolidated interim
financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)
Attributable to the owners of the company | ||||||||||||||
Accumulated | ||||||||||||||
other | ||||||||||||||
Subscribed | Capital | Accumulated | comprehensive | Non-controlling | ||||||||||
(€ in thousands) | capital | reserves | deficit | gain (loss) | Total | interests | Total equity | |||||||
Balance at December 31, 2017 (2) | 3,720 | 76,227 | (37,480) | 1,380 | 43,847 | 71 | 43,918 | |||||||
Adjustment on initial application of IFRS 15 | — | — | (100) | — | (100) | — | (100) | |||||||
Adjustment on initial application of IFRS 9 | — | — | (63) | — | (63) | — | (63) | |||||||
Adjusted balance at January 1, 2018 (2) | 3,720 | 76,227 | (37,643) | 1,380 | 43,684 | 71 | 43,755 | |||||||
Loss for the period | — | — | (1,710) | — | (1,710) | (6) | (1,716) | |||||||
Net changes in fair value of debt investments at FVOCI | — | — | — | (15) | (15) | — | (15) | |||||||
Foreign currency translations | — | — | — | (64) | (64) | — | (64) | |||||||
Equity-settled share-based payment | — | 129 | — | — | 129 | — | 129 | |||||||
Balance at March 31, 2018 (2) | 3,720 | 76,356 | (39,353) | 1,301 | 42,024 | 65 | 42,089 |
Attributable to the owners of the company | ||||||||||||||
Accumulated | ||||||||||||||
other | ||||||||||||||
Subscribed | Capital | Accumulated | comprehensive | Non-controlling | ||||||||||
(€ in thousands) | capital | reserves | deficit | gain (loss) | Total | interests | Total equity | |||||||
Balance at December 31, 2018 (1) | 4,836 | 86,803 | (46,400) | 1,201 | 46,440 | 35 | 46,475 | |||||||
Loss for the period | — | — | (2,784) | — | (2,784) | (4) | (2,788) | |||||||
Net changes in fair value of debt investments at FVOCI | — | — | — | 106 | 106 | — | 106 | |||||||
Foreign currency translations | — | — | — | (400) | (400) | — | (400) | |||||||
Equity-settled share-based payment | — | 165 | — | — | 165 | — | 165 | |||||||
Share-based payment transaction with the non-controlling shareholder of a subsidiary |
— | 604 | — | — | 604 | 216 | 820 | |||||||
Balance at March 31, 2019 | 4,836 | 87,572 | (49,184) | 907 | 44,131 | 247 | 44,378 |
See accompanying notes to unaudited condensed consolidated interim
financial statements.
(1)The Company has initially applied IFRS 16 as of January 1,
2019, using the modified retrospective approach. Under this approach,
comparative information is not restated and the cumulative effect of
initially applying IFRS 16 is recognized in retained earnings at the
date of initial application. For further information, see Note 2 of the
condensed consolidated interim financial statements.
(2)Certain comparative figures for the 3-month period ended
March 31, 2018 were restated for immaterial errors. For further
information, see Note 9 of the Q3-2018 condensed consolidated interim
financial statements.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Three months ended March 31, | ||||
2019 | 2018 (1) (2) | |||
(€ in thousands) | ||||
Cash Flow from operating activities | ||||
Loss for the period | (2,788) | (1,716) | ||
Depreciation and amortization | 1,050 | 841 | ||
Foreign currency exchange differences on loans to subsidiaries | (769) | (61) | ||
Share-based compensation expense | 165 | 129 | ||
Change in impairment of trade receivables | (28) | 10 | ||
Non-cash interest expense on long-term debt | 205 | 189 | ||
Change in fair value of derivative equity forward | 602 | (941) | ||
Change in inventory allowance | (9) | (226) | ||
Other | — | 9 | ||
Change in working capital | (265) | 1,578 | ||
Trade and other receivables, inventories and current assets | 61 | (901) | ||
Trade payables | (586) | (260) | ||
Other liabilities, contract liabilities and provisions | 284 | 2,739 | ||
Income tax payable/receivables | (24) | — | ||
Net cash used in operating activities | (1,837) | (188) | ||
Cash Flow from investing activities | ||||
Payments to acquire property, plant and equipment and intangible assets |
(173) | (234) | ||
Proceeds from disposal of financial assets | 4,081 | 2,526 | ||
Payments to acquire financial assets | (1,235) | (6,170) | ||
Proceeds from disposal of property, plant and equipment | 22 | — | ||
Net cash from (used in) investing activities | 2,695 | (3,878) | ||
Cash Flow from financing activities | ||||
Repayment of bank overdrafts and lines of credit | — | (58) | ||
Repayment of sale and leaseback obligation | — | (118) | ||
Repayment of lease liabilities (2018: Repayment of finance lease obligations) |
(77) | (12) | ||
Repayment of long-term debt | (250) | (197) | ||
Proceeds from issuance of long-term debt | 500 | 40 | ||
Net cash from (used in) financing activities | 173 | (345) | ||
Net increase (decrease) in cash and cash equivalents | 1,031 | (4,411) | ||
Cash and cash equivalents at beginning of period | 7,402 | 7,569 | ||
Changes to cash and cash equivalents due to foreign exchanges rates | 49 | (18) | ||
Cash and cash equivalents at end of period | 8,482 | 3,140 | ||
Supplemental Cash Flow Information | ||||
Interest paid | 66 | 47 | ||
Interest received | 43 | 1 |
Contacts
Investors and Media
Johannes Pesch
Director Investor
Relations and Business Development
[email protected]
Office:
+49 821 7483172
Mobile: +49 176 45398316
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493
Cannabis
Rubicon Organics Reports Q1 2024 Financial Results
SCHWAZZE
Schwazze Announces First Quarter 2024 Financial Results
Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time
DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.
“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”
“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”
“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”
“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”
First Quarter 2024 Financial Summary
$ in Thousands USD |
Q1 2024 |
Q4 2023 |
Q1 2023 |
Total Revenue |
$41,601 |
$43,325 |
$40,001 |
Gross Profit |
$17,934 |
$7,034[1] |
$21,849 |
Operating Expenses |
$20,643 |
$23,276 |
$16,199 |
Income (Loss) from Operations |
$(2,709) |
$(16,242) |
$5,650 |
Adjusted EBITDA[2] |
$7,341 |
$10,953 |
$14,525 |
Operating Cash Flow |
$(3,700) |
$3,452 |
$(880) |
Recent Highlights
- Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
- Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
- Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
- Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.
First Quarter 2024 Financial Results
Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.
Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.
____________________________ |
1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. |
Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.
Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.
Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.
As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.
Conference Call
The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.
Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].
Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call
The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.
Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910
If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.
About Schwazze
Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.
Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.
Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.
Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars
March 31, |
December 31, |
||||
2024 |
2023 |
||||
ASSETS
|
|||||
Current Assets |
|||||
Cash & Cash Equivalents |
$ |
13,151,317 |
$ |
19,248,932 |
|
Accounts Receivable, net of Allowance for Doubtful Accounts |
3,356,032 |
4,261,159 |
|||
Inventory |
26,382,184 |
25,787,793 |
|||
Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively |
108,583 |
456,099 |
|||
Prepaid Expenses & Other Current Assets |
3,502,310 |
3,914,064 |
|||
Total Current Assets |
46,500,426 |
53,668,047 |
|||
Non-Current Assets |
|||||
Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively |
31,326,000 |
31,113,630 |
|||
Investments |
2,000,000 |
2,000,000 |
|||
Investments Held for Sale |
– |
202,111 |
|||
Goodwill |
67,492,705 |
67,499,199 |
|||
Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively |
162,391,482 |
166,167,877 |
|||
Other Non-Current Assets |
1,328,187 |
1,263,837 |
|||
Operating Lease Right of Use Assets |
34,575,832 |
34,233,142 |
|||
Deferred Tax Assets, net |
992,144 |
1,996,489 |
|||
Total Non-Current Assets |
300,106,350 |
304,476,285 |
|||
Total Assets |
$ |
346,606,776 |
$ |
358,144,332 |
|
LIABILITIES & STOCKHOLDERS’ EQUITY
|
|||||
Current Liabilities |
|||||
Accounts Payable |
$ |
9,443,233 |
$ |
13,341,561 |
|
Accrued Expenses |
8,106,618 |
7,774,691 |
|||
Derivative Liabilities |
1,319,845 |
638,020 |
|||
Lease Liabilities – Current |
5,186,316 |
4,922,724 |
|||
Current Portion of Long Term Debt |
29,579,713 |
3,547,011 |
|||
Income Taxes Payable |
28,235,039 |
25,232,782 |
|||
Total Current Liabilities |
81,870,764 |
55,456,789 |
|||
Non-Current Liabilities |
|||||
Long Term Debt, net of Debt Discount & Issuance Costs |
130,120,753 |
153,262,203 |
|||
Lease Liabilities – Non-Current |
30,735,072 |
30,133,452 |
|||
Total Non-Current Liabilities |
160,855,825 |
183,395,655 |
|||
Total Liabilities |
$ |
242,726,589 |
$ |
238,852,444 |
|
Stockholders’ Equity |
|||||
Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and |
|||||
82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of |
|||||
December 31, 2023. |
82 |
86 |
|||
Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued |
|||||
and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued |
|||||
and 73,968,242 Shares Outstanding as of December 31, 2023. |
79,169 |
74,888 |
|||
Additional Paid-In Capital |
202,677,665 |
202,040,968 |
|||
Accumulated Deficit |
(96,843,602) |
(80,790,927) |
|||
Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and |
|||||
920,150 Shares Held as of December 31, 2023. |
(2,033,127) |
(2,033,127) |
|||
Total Stockholders’ Equity |
103,880,187 |
119,291,888 |
|||
Total Liabilities & Stockholders’ Equity |
$ |
346,606,776 |
$ |
358,144,332 |
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
(Unaudited) |
(Unaudited) |
||||
Operating Revenues |
|||||
Retail |
$ |
37,633,252 |
$ |
35,820,111 |
|
Wholesale |
3,898,320 |
4,058,925 |
|||
Other |
69,421 |
121,900 |
|||
Total Revenue |
41,600,993 |
40,000,936 |
|||
Total Cost of Goods & Services |
23,667,319 |
18,152,163 |
|||
Gross Profit |
17,933,674 |
21,848,773 |
|||
Operating Expenses |
|||||
Selling, General and Administrative Expenses |
11,835,818 |
10,100,934 |
|||
Professional Services |
1,671,881 |
1,187,364 |
|||
Salaries |
6,880,988 |
4,695,971 |
|||
Stock Based Compensation |
253,916 |
214,544 |
|||
Total Operating Expenses |
20,642,603 |
16,198,813 |
|||
Income from Operations |
(2,708,929) |
5,649,960 |
|||
Other Income (Expense) |
|||||
Interest Expense, net |
(8,307,369) |
(7,745,854) |
|||
Unrealized Gain (Loss) on Derivative Liabilities |
(681,825) |
8,501,685 |
|||
Other Loss |
10,500 |
– |
|||
Loss on Investment |
(33,382) |
– |
|||
Unrealized Gain on Investment |
(347,516) |
1,816 |
|||
Total Other Income (Expense) |
(9,359,592) |
757,647 |
|||
Pre-Tax Net Income (Loss) |
(12,068,521) |
6,407,607 |
|||
Provision for Income Taxes |
3,984,154 |
4,662,178 |
|||
Net Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Less: Accumulated Preferred Stock Dividends for the Period |
(2,155,259) |
(2,029,394) |
|||
Net Income (Loss) Attributable to Common Stockholders |
$ |
(18,207,934) |
$ |
(283,965) |
|
Earnings (Loss) per Share Attributable to Common Stockholders |
|||||
Basic Earnings (Loss) per Share |
$ |
(0.24) |
$ |
(0.01) |
|
Diluted Earnings (Loss) per Share |
$ |
(0.24) |
$ |
(0.06) |
|
Weighted Average Number of Shares Outstanding – Basic |
76,006,932 |
55,835,501 |
|||
Weighted Average Number of Shares Outstanding – Diluted |
76,006,932 |
101,608,278 |
|||
Comprehensive Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
(Unaudited) |
(Unaudited) |
||||
Cash Flows from Operating Activities: |
|||||
Net Income (Loss) for the Period |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities |
|||||
Depreciation & Amortization |
5,096,314 |
6,151,395 |
|||
Non-Cash Interest Expense |
1,031,431 |
991,184 |
|||
Non-Cash Lease Expense |
2,871,226 |
2,251,459 |
|||
Deferred Taxes |
1,004,345 |
(637,225) |
|||
Loss on Investment |
202,111 |
– |
|||
Change in Derivative Liabilities |
681,825 |
(8,501,685) |
|||
Amortization of Debt Issuance Costs |
421,512 |
421,513 |
|||
Amortization of Debt Discount |
2,303,246 |
1,999,933 |
|||
(Gain) Loss on Investments, net |
347,516 |
(1,816) |
|||
Stock Based Compensation |
640,974 |
214,544 |
|||
Changes in Operating Assets & Liabilities (net of Acquired Amounts): |
|||||
Accounts Receivable |
905,127 |
(118,181) |
|||
Inventory |
(587,900) |
(3,023,251) |
|||
Prepaid Expenses & Other Current Assets |
411,754 |
(3,036,801) |
|||
Other Assets |
(64,350) |
360,674 |
|||
Change in Operating Lease Liabilities |
(2,348,703) |
(1,531,765) |
|||
Accounts Payable & Other Liabilities |
(3,566,401) |
(3,464,671) |
|||
Income Taxes Payable |
3,002,257 |
5,299,403 |
|||
Net Cash Provided by (Used in) Operating Activities |
(3,700,390) |
(879,861) |
|||
Cash Flows from Investing Activities: |
|||||
Collection of Notes Receivable |
– |
10,631 |
|||
Purchase of Fixed Assets |
(1,532,287) |
(2,913,394) |
|||
Net Cash Provided by (Used in) Investing Activities |
(1,532,287) |
(2,902,763) |
|||
Cash Flows from Financing Activities: |
|||||
Payment on Notes Payable |
(864,938) |
– |
|||
Net Cash Provided by (Used in) Financing Activities |
(864,938) |
– |
|||
Net (Decrease) in Cash & Cash Equivalents |
(6,097,615) |
(3,782,624) |
|||
Cash & Cash Equivalents at Beginning of Period |
19,248,932 |
38,949,253 |
|||
Cash & Cash Equivalents at End of Period |
$ |
13,151,317 |
$ |
35,166,628 |
|
Supplemental Disclosure of Cash Flow Information: |
|||||
Cash Paid for Interest |
$ |
4,515,205 |
$ |
6,540,748 |
MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars
For the Three Months Ended |
|||||
March 31, |
|||||
2024 |
2023 |
||||
Net Income (Loss) |
$ |
(16,052,675) |
$ |
1,745,429 |
|
Interest Expense, net |
8,307,369 |
7,745,854 |
|||
Provision for Income Taxes |
3,984,154 |
4,662,178 |
|||
Other (Income) Expense, net of Interest Expense |
1,052,223 |
(8,503,501) |
|||
Depreciation & Amortization |
5,618,834 |
6,612,814 |
|||
Earnings Before Interest, Taxes, Depreciation and |
|||||
Amortization (EBITDA) (non-GAAP) |
$ |
2,909,905 |
$ |
12,262,774 |
|
Non-Cash Stock Compensation |
253,916 |
214,544 |
|||
Deal Related Expenses |
637,761 |
1,195,802 |
|||
Capital Raise Related Expenses |
20,760 |
35,068 |
|||
Severance |
484,561 |
118,436 |
|||
Retention Program Expenses |
807,500 |
280,632 |
|||
Pre-Operating & Dark Carry Expenses |
1,053,837 |
391,917 |
|||
One-Time Legal Settlements |
417,653 |
– |
|||
Other Non-Recurring Items |
754,751 |
25,707 |
|||
Adjusted EBITDA (non-GAAP) |
$ |
7,340,644 |
$ |
14,524,880 |
|
Revenue |
41,600,993 |
40,000,936 |
|||
Adjusted EBITDA Percent |
17.6 % |
36.3 % |
View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html
Cannabis
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Announces First Shipment of Cannabis Essential Oil from Colombia to U.S. to Fill First Order, as the DEA Re-Classifies Marijuana from Schedule I to Schedule III
-
Cannabis1 week ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis1 week ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Innocan7 days ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis3 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis3 days ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
Cannabis2 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
-
Cannabis22 hours ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032